| Ryanodine Receptor 1 | |
|---|---|
| Gene Symbol | RYR1 |
| Full Name | Ryanodine Receptor 1 |
| Chromosome | 19q13.2 |
| NCBI Gene ID | [6261](https://www.ncbi.nlm.nih.gov/gene/6261) |
| OMIM | 180901 |
| Ensembl ID | ENSG00000196218 |
| UniProt ID | [P21810](https://www.uniprot.org/uniprot/P21810) |
| Protein Length | 5,038 amino acids |
| Expression | Skeletal muscle, brain (neurons) |
| Associated Diseases | Central Core Disease, Malignant Hyperthermia, Alzheimer's Disease, Parkinson's Disease |
RYR1 (Ryanodine Receptor 1) encodes the skeletal muscle calcium release channel, a massive intracellular ion channel responsible for triggering muscle contraction through the release of calcium from the sarcoplasmic reticulum (SR)[1]. As the largest known ion channel complex, RYR1 forms a homotetramer of approximately 2.2 MDa, serving as the primary pathway for calcium-induced calcium release (CICR) in skeletal muscle cells. The discovery and cloning of RYR1 in the 1980s revolutionized our understanding of excitation-contraction (EC) coupling and continues to inform research into muscle physiology and disease[2][3].
While RYR1 is predominantly expressed in skeletal muscle, significant expression also occurs in select neuronal populations within the central nervous system, particularly in the hippocampus, cerebellum, and various cortical regions[4]. Neuronal RYR1 plays crucial roles in regulating intracellular calcium dynamics, synaptic plasticity, and neuronal homeostasis. Dysregulation of neuronal RYR1 has been increasingly recognized as a contributing factor in the pathogenesis of neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), and related disorders[5].
RYR1 is an enormous protein comprising 5,038 amino acids that forms a homotetrameric channel complex[6]. Each monomer contains:
Skeletal Muscle EC Coupling:
Calcium-Induced Calcium Release (CICR):
| Regulator | Effect | Mechanism |
|---|---|---|
| Calcium | Activation | Direct binding to activation sites |
| Mg2+ | Inhibition | Competes with Ca2+ at activation sites |
| ATP | Activation | Stabilizes open state |
| Caffeine | Activation | Lowers activation threshold |
| Reactive oxygen species | Variable | Oxidative modifications |
| Calmodulin | Biphasic | Ca2+-dependent activation/inhibition |
Within the nervous system, RYR1 exhibits a selective distribution[4:1]:
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Hippocampus | Moderate-High | CA1-CA3 pyramidal neurons |
| Cerebellum | High | Purkinje cells |
| Cerebral Cortex | Moderate | Layer 5 pyramidal neurons |
| Basal Ganglia | Moderate | Striatal medium spiny neurons |
| Spinal Cord | High | Motor neurons |
In neurons, RYR1 localizes to:
RYR1 dysfunction plays a significant role in AD pathogenesis through multiple mechanisms[7][8][5:1]:
Calcium Dysregulation Hypothesis:
The calcium dysregulation hypothesis of AD posits that altered calcium signaling is a fundamental early event in disease pathogenesis. RYR1 contributes through:
Consequences:
In Parkinson's disease, RYR1 contributes to dopaminergic neuron vulnerability[9]:
Mechanisms of Neurodegeneration:
Therapeutic Implications:
RYR1 dysfunction is implicated in:
In skeletal muscle, RYR1 serves as the final effector of EC coupling:
Neuronal RYR1 plays essential roles in synaptic plasticity[10]:
Long-Term Potentiation (LTP):
Long-Term Depression (LTD):
| Partner | Interaction Type | Functional Effect |
|---|---|---|
| Cav1.1 (skeletal) | Mechanical coupling | EC coupling trigger |
| Calmodulin | Calcium-dependent binding | Biphasic regulation |
| FKBP12 | Stabilizing binding | Enhanced channel function |
| Calsequestrin | Calcium storage | Calcium buffering |
| Junctophilin | Structural | T-SR anchoring |
| TRPC channels | Calcium influx | Store-operated entry |
Given the role of RYR1 dysregulation in neurodegeneration, therapeutic strategies include[11]:
Challenges:
Knockout Models:
Transgenic Models:
Over 300 pathogenic RYR1 mutations cause:
Some RYR1 variants may modify neurodegenerative disease risk.
| Compound | Target | Phase | Status | Indication |
|---|---|---|---|---|
| Dantrolene | RYR1 | II/III | Approved (MH) | Malignant Hyperthermia |
| Dexmedetomidine | RYR1 | II | Completed | Perioperative neuroprotection |
| S48168 | RYR1 | I | Completed | Heart failure |
Clinical Development Status:
Challenges in RYR1-Targeted Therapy:
RYR1 represents a critical nexus linking calcium signaling to both muscle function and neuronal health. Originally studied for its essential role in skeletal muscle contraction, RYR1 has emerged as an important player in neurodegenerative disease pathogenesis. The channel's dysfunction contributes to calcium dysregulation, mitochondrial failure, oxidative stress, and synaptic impairment—all hallmarks of AD, PD, and related disorders.
Fill M, Copello JA. Ryanodine receptor calcium release channels. Physiol Rev. 2002. ↩︎
Zorzato F, et al. Molecular cloning of the rabbit skeletal muscle ryanodine receptor. J Biol Chem. 1985. ↩︎
MacLennan DH, et al. Structure of the Ca2+ release channel of skeletal muscle. Nature. 1989. ↩︎
Du GN, et al. Neuronal ryanodine receptors: expression and function in brain. Neuroscientist. 2002. ↩︎ ↩︎
Bermek O, et al. Ryanodine receptor dysfunction in neurodegenerative diseases. Nat Rev Neurosci. 2021. ↩︎ ↩︎
Van Petegem F. Ryanodine receptors: structure and function. J Biol Chem. 2008. ↩︎
Stutzmann GE. Calcium dysregulation in Alzheimer's disease: what is the evidence?. Neuroscientist. 2006. ↩︎
Mattson MP. Calcium and neurodegeneration. Aging Cell. 2008. ↩︎
Chen X, et al. Calcium dysregulation in Parkinson's disease models. Cell Rep. 2023. ↩︎
Gomez M, et al. Ryanodine receptors in synaptic plasticity and memory. Learn Mem. 2019. ↩︎
Hernandez-Vivanco L, et al. Selective ryanodine receptor antagonists as neuroprotective agents. J Med Chem. 2021. ↩︎